R eperfusion of tissue after revascularization of an arterial thrombosis or preservation of a solid-organ allograft is accompanied by microvascular endothelial cell injury, local activation of the coagulation cascade, and diminished endothelial anticoagulant properties. [1] [2] [3] In addition, platelet and leukocyte adhesion to the endothelium is thought to contribute to inhomogeneous perfusion and persistent ischemic injury of the parenchymal cells of the tissue. 4 -6 Activation of specific receptors on the microvascular endothelial cells by the serine proteinases of the coagulation cascade appears to be an important mechanistic link between tissue injury and the early recruitment of leukocytes. 2 The proteinase activated receptors (PARs) are a novel family of G protein-coupled receptors that require proteolytic cleavage at the amino terminus to stimulate signaling (see review 7 ). Cleavage allows the newly exposed tethered ligand to initiate an intramolecular interaction necessary for signal transduction, which can be mimicked by peptide analogues of the newly exposed N-terminus. The PAR family members, PAR [1] [2] [3] [4] , are expressed constitutively on endothelial cells, and PAR 2 and PAR 4 are further upregulated on inflamed endothelium. 8, 9 PAR 1 , PAR 3 , and PAR 4 are substrates for thrombin, whereas PAR 2 can be stimulated by the activity of tryptase, a product of mast cell degranulation, and coagulation Factors VIIa and Xa. 10, 11 Stimulation of endothelial cells with thrombin or peptide analogues of the PAR 1 -tethered ligand (eg, TRAP or SFLLRN-NH 2 ), results in reorganization of the cytoskeleton and discharge of endothelial storage granules, or WeibelPalade bodies (WPBs). Exocytosis of WPBs plays a major role in the recruitment of leukocytes to sites of inflammation. 12 WP body exocytosis releases stored IL-8 and mobilizes the adhesion molecule P-selectin to the lumenal surface of the endothelial cell. 13, 14 In addition, WPB exocytosis promotes platelet adhesion through the release of von Willebrand's factor (vWF). 13 Thrombin stimulation elicits capillary leak in vivo and increased endothelial monolayer permeability in vitro. 15, 16 PAR stimulation, then, promotes leukocyte adhesion to vascular endothelium and links inflammation and coagulation in a variety of pathological settings.
Stimulation of the PAR 2 is also proinflammatory in vivo. Injection of selective peptide analogues of the PAR 2 receptor tethered ligand is sufficient to initiate inflammation in vivo. 17 Moreover, impaired inflammatory responses are observed in the PAR 2 -deficient mouse. 18 In vitro, trypsin, like thrombin or TRAP, treatment elicits WPB exocytosis, 19 but fails to induce monolayer permeability. 20 However, the proteinases may act on surface proteins other than PARs, 21 and the PAR 1 agonist peptides modeled on the PAR 1 tethered ligand activate both PAR 1 and PAR 2 . 22 Hence, characterization of the effects of selective endothelial PAR 2 stimulation, and the signaling pathways recruited by PAR 2 agonists to stimulate the endothelial cell remain to be explored.
Materials and Methods

Reagents
PAR agonist peptides (AP) TFFLR-NH 2 , and SLIGRL-NH 2 were obtained from the peptide synthesis facility of the Health Sciences Center of the University of Calgary or from the Alberta Peptide Institute and were Ͼ95% pure by HPLC. Jasplakinolide was obtained from Molecular Probes. ELISA reagents for vWF quantitation, were obtained from Cedarlane Laboratories, and a vWF standard through Precision Biologic. Ionomycin and C3 exotoxin were obtained from Calbiochem. The rho-kinase inhibitor Y-27632 was a gift of Welfide Corporation (Osaka, Japan). The Clostridium difficile toxin B (TcdB) was obtained from List Biochemicals. The rhotekin Rho binding domain (RBD)-GST fusion protein cDNA was a generous gift of Dr M. Schwartz (Scripps Research Institute, San Diego, Calif). Anti-RhoA mAb 26C4, and phospho-specific myosin light chain kinase pAb, were obtained from Santa Cruz Biotechnology. Peroxidase-conjugated secondary pAb were from Jackson Immunoresearch. M199, FBS, and Hanks balanced salt solution were from Invitrogen. Cell dissociation solution, cytochalasin D, H-7, and all other reagents were from Sigma.
Endothelial Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated from several umbilical cords, pooled, and cultured in complete media (M199 with 20% FBS, penicillin, streptomycin, and glutamine). 23 Cells were serially passed in complete media supplemented with ECGS. HUVECs were cultured on a gelatin matrix and used in the experiments at passage 2 to 5. The passaged endothelial cells were harvested by washing twice with Hanks', then incubated with a nonenzymatic Cell Dissociation Solution (Sigma) until the ECs were seen to lift off the plate. For use in an experiment, the harvested cells were then replated onto fibronectin (Fn)-coated C6 wells and incubated at 37°C in complete medium for 24 to 48 hours until confluent.
Where indicated, Cytochalasin D (1 mol/L), jasplakinolide (45 nmol/L), or DMSO vehicle were diluted in supplemented M199 and added to the existing media. After 1 hour of incubation at 37°C, the media was removed and discarded, and fresh complete media with the agonist or vehicle diluted to the desired concentration was applied to the HUVECs. To inhibit Rho-GTPases, HUVECs were pretreated with 50 g/mL C3 exotoxin for 24 hours and a mobility shift of endothelial Rho on SDS-PAGE was confirmed as described previously. 24 To inhibit rho-kinase, endothelial cells were pretreated with H-7 (0.5 mol/L) or Y-27632 (15 mol/L) for 120 minutes before stimulation. To stimulate WP body exocytosis, the following agonists were used: phorbal 12-myristate 13-acetate (PMA) at 100 nmol/L, PAR 1 AP (TFLLR-NH 2 ) at 30 mol/L, PAR 2 AP (SLIGRL-NH 2 ) at 30 mol/L, and Ionomycin at 1 mol/L, except where otherwise specified.
Chemical inhibitors were used at concentrations that maintained HUVEC viability Ͼ85% of mock-treated controls as assessed by the XTT assay of mitochondrial activity. 25 
ELISA Assay of vWF
Supernatant from mock-or agonist-stimulated HUVECs was removed into separate tubes and kept on ice until analysis. The vWF concentration was determined by ELISA. Calibration was performed with a vWF standard (Human reference plasma, Precision Biologics). Regulated vWF release was calculated by subtracting the vWF concentration in unstimulated wells from the stimulated wells. The effect of the inhibitors was determined by comparing the mean vWF release to its control group. The mean difference of the treatment among several experiments, as noted in the figure legends, was calculated and tested for statistical significance (PϽ0.05) by ANOVA using SPSS (SPSS).
Endothelial Monolayer Permeability
HUVECs at passage 3 were plated onto fibronectin-coated polycarbonate membranes (5-um pore size Transwell, Costar) at 6ϫ10 4 cells/cm 2 in M199/20% FBS. The monolayers were cultured for 5 days with media changes every 2 days and were not disturbed for 24 hours before the experiment. Horse radish peroxidase (HRP, MW 44kDa, Sigma) was added to the upper chamber at a final concentration of 1 g/ml, then the specific peptide agonist was added at the concentration indicated in the figure legends. Where indicated, the monolayers were pretreated as described in the figure legend. Medium was harvested from the lower chamber after 20 minutes, and the HRP activity was determined colorimetrically by absorbance at 490 nm of the o-phenyl diamine reaction product. The mean HRP concentration from triplicate experimental wells was compared with the HRP concentration in wells treated with ionomycin 10 mol/L according to the formula: (experimentalϪmedia control)/ (ionomyinϪmedia control)ϫ100ϭ% maximum permeability.
The difference of the means between treatment and controls among several experiments was calculated and tested for statistical significance (PϽ0.05) by ANOVA using SPSS.
Affinity Precipitation of Rho-GTP
The RBD-GST fusion protein was prepared and isolated using glutathione beads (Amersham, Baie d'Urfe, PQ), then used to affinity precipitate GTP-Rho as described previously. 26 Rho was detected with anti-Rho mAb 26C4 then the blots were developed using chemiluminescence (Supersignal, Pierce). Images were acquired from film using a CCD camera and the density of the bands were quantitated using the Fluor-S Max software package (BioRad).
Transient Transfection of Endothelial Cells
Dominant-negative myc-tagged mutant Rac1 17N and Cdc42 17N cDNA were generously provided by Dr Gary Bokoch (Scripps) then subcloned into pCSD7 (a gift of John Elliott, University of Alberta, Edmonton, Canada) for transfection of HUVECs. The cDNAs were sequenced to confirm the presence of the mutation before use. Briefly, HUVECs were plated at confluence on Fn matrix in C-6 plates in growth medium 1 day before transfection. The cells were washed with OptiMEM (Life Technologies), then 0.2 g DNA/well was introduced into the cells using the Effectene kit (Qiagen) according to the instructions of the manufacturer. After 3 to 4 hours, the wells were washed and the media was replaced with M199/10% FBS and ECGS. Pilot experiments indicated that expression of the myc-tagged mutant GTPase was optimal at approximately 24 hours after transfection; therefore, the cells were used in the experiments as indicated at this time. Endothelial cell expression of the myc-tagged protein was confirmed in each experiment.
Results
Weibel-Palade Body Exocytosis Is Stimulated by Activating Peptides Specific for PAR 2
First, we sought to examine the effect of selective PAR 2 activation compared with PAR 1 activation on endothelial cell Figure 2 ). Ionomycin stimulation elicited a marked increase in transfer of HRP across the monolayer (18Ϯ6 versus 68Ϯ7 ng/cm 2 per hour; meanϮSEM) and served as a comparator to which the effects of the PAR agonists were normalized. These data indicate that although PAR 2 , like PAR 1 stimulation, is able to induce bundled f-actin stress fiber formation, unlike PAR 1 , PAR 2 fails to induce pore formation.
Effect of Cytochalasin D and Jasplakinolide on PAR 2 Agonist Peptide-Stimulated Exocytosis
Both endothelial cell exocytosis and monolayer permeability changes are thought to require rearrangement of the f-actin cytoskeleton, hence we sought to determine if PAR 2 stimulated f-actin reorganization. Cytochalasin D and jasplakinolide have been previously shown to depolymerize or stabilize the f-actin cytoskeleton, respectively. 27, 28 To determine if the endothelial cytoskeleton was reorganized in PAR 2 -stimulated regulated exocytosis, HUVECs were pretreated with either agent, then treated or not with peptide agonist. Neither agent changed constitutive vWF release. However, cytochalasin D pretreatment led to a modest augmentation of both PAR 2 -and PAR 1 -regulated WP body exocytosis (Figure 3 ). These data indicate that an intact cytoskeleton is not required for PARstimulated WP body exocytosis.
Jasplakinolide was used to test the requirements of each agonist for remodeling of the intact cytoskeleton to elicit vWF release (Figure 3 ). HUVECs pretreated with jasplakinolide then stimulated with PAR 1 agonist peptide, TFLLR-NH 2 , released 54Ϯ15% of vWF compared with mock-pretreated cells (Pϭ0.03, nϭ6 experiments). Similarly, jasplakinolide inhibited vWF release on stimulation with PAR 2 agonist peptide, SLIGRL-NH 2 , to 43Ϯ16% of mock-pretreatment release (Pϭ0.05, nϭ5 experiments). These data indicate that PAR 2 -mediated exocytosis requires active remodeling of the endothelial f-actin cytoskeleton. 
PAR 2 Exocytosis Requires Intracellular Calcium
The initiation of a calcium flux has previously been identified to play a critical role in thrombin-stimulated WP body exocytosis and monolayer permeability. 29, 30 To determine if PAR 2 -stimulated exocytosis was similarly dependent on calcium-dependent signaling, HUVEC monolayers were pretreated with BAPTA-AM, then stimulated with the PAR agonist peptides. As noted in Figure 4A , PAR 2 -stimulated vWF release was markedly inhibited under these conditions. This indicates that WP body exocytosis, stimulated by either PAR 1 or PAR 2 , is dependent on elevated intracellular calcium concentration.
Our data suggest that both cytoskeletal reorganization and elevated intracellular calcium are required for efficient PARstimulated exocytosis. However, high concentrations of jasplakinolide may inhibit sustained intracellular calcium levels after stimulation via G protein-coupled receptors. 31 Because a calcium flux is sufficient to induce WP body exocytosis, 29 we sought to determine if calcium ionophore-induced vWF release was affected by jasplakinolide. First, HUVECs were stimulated with ionomycin to define a concentration-effect curve (data not shown). Ionomycin (1 mol/L) induced vWF release comparable to that of the PAR-activating peptides at 30 to 50 mol/L. Jasplakinolide pretreatment diminished ionomycin-induced vWF release to 52Ϯ13% (Figure 4B ; Pϭ0.02, nϭ5 experiments) of mock-pretreated controls. This observation indicates that the effect of jasplakinolide lies downstream of the generation of a calcium flux and suggests that PAR 2 stimulation results in a calcium-dependent reorganization of the endothelial cytoskeleton.
Involvement of Rho-GTPase Signaling After PAR 2 Stimulation
The Rho family of small GTP-binding proteins regulate the f-actin cytoskeleton and have been implicated in thrombinstimulated increased endothelial monolayer permeability, 16, 32 and in exocytosis in a variety of other cell types. 33, 34 Rho kinase, a Rho-GTP-dependent serine/threonine kinase, acts to phosphorylate and inactivate myosin light chain phosphatase. Myosin light chain phosphorylation is also implicated in both thrombin-stimulated permeability and exocytosis. 16, 29 We therefore sought to determine if a Rho-GTPasedependent signaling pathway was recruited after PAR 2 stimulation.
We pretreated confluent HUVEC monolayers with TcdB toxin to selectively inhibit the small GTPases, Rho, Rac, and Cdc42. PAR 2 -and PAR 1 -mediated exocytosis were markedly inhibited ( Figure 5A ). This strongly suggests that RhoGTPases serve a critically important function to effect PARstimulated exocytosis in endothelial cells.
To determine if RhoA activity elicited by PAR 2 stimulation was involved in exocytosis, we tested the effect of specific inhibitors of the RhoA signaling pathway. First, we inhibited Rho activity with C3 exotoxin. 24 C3 pretreatment did not inhibit vWF release using the PAR 2 agonist peptide to stimulate endothelial cell exocytosis ( Figure 5A ). We similarly observed that inhibition of Rho-kinase with either Y-27632 or H-7 (data not shown) failed to inhibit, and tended to augment, PAR-stimulated vWF release. In contrast, PAR 1 stimulation of monolayer permeability was markedly attenuated by inhibition of Rho kinase with Y-27632 (Figure 2 ). These data indicate that RhoA-GTPase signaling is not required for PAR 2 -stimulated exocytosis and suggest that other Rho-GTPase family members account for the TcdBmediated inhibition.
To identify the Rho-GTPase family member involved in PAR-stimulated exocytosis, we expressed dominant- ( Figure 5B ). Taken together these observations indicate that stimulation of either endothelial PAR receptor recruits a signal that is dependent on Cdc42 activity to elicit exocytosis.
PAR 2 Stimulation Elicits Weak RhoA Activity
PAR 1 -stimulated monolayer permeability depends on Rho kinase activity (Figure 2 ), hence we directly assessed RhoA activation after PAR 2 stimulation to determine if the failure of PAR 2 to elicit pore formation correlated with RhoA-GTP. As shown in Figure 6 , RhoA-GTP was robustly activated by PAR 1 stimulation, but only weakly by PAR 2 stimulation at receptor-selective concentrations of the agonist peptides. To determine if the weak RhoA-GTP stimulation by PAR 2 could account for the failure of pore formation through failing to increase cell contractility, we examined myosin light chain phosphorylation. Both PAR 2 and PAR 1 agonist peptides induced phosphorylation of myosin light chain, with a much greater effect of PAR 1 (Figure 7) . Interestingly, stimulation of MLC phosphorylation by either agonist peptide was inhibited by pretreatment of the HUVECs with Y27632 (data not shown). These observations indicate that the failure of PAR 2 stimulation to elicit monolayer pore formation correlates with weak signaling through RhoA.
Discussion
The major observations of this article are as follows: first, PAR 2 -stimulated exocytosis is dependent on both remodeling the actin cytoskeleton and eliciting an intracellular calcium flux. PAR 2 -stimulated exocytosis does not require either myosin light chain phosphorylation, or RhoA-GTPasedependent Rho kinase activity. However, both PAR 2 and PAR 1 -stimulated exocytosis is sensitive to TcdB inhibition of the Rho family of GTPases. Cdc42 signaling appears to be the principal Rho-GTPase required for endothelial WeibelPalade body exocytosis. Interestingly, unlike PAR 1 , PAR 2 failed to elicit increased endothelial monolayer permeability, despite generating stress fibers and myosin light chain phosphorylation to enable cell contractility. Activity of RhoA-GTP and myosin light chain phosphorylation are required for PAR 1 -mediated monolayer permeability. We studied selective agonists of both the PAR 2 and PAR 1 G protein-coupled receptors and observed that each stimulated similar amounts of vWF release from the endothelial cell storage pool. The use of a selective activator of PAR 2 indicates that the PAR 2 system can have as great an impact on Weibel-Palade body exocytosis and hence lumenal display of P-selectin as the thrombin-regulated PAR 1 system. Interestingly, like PAR 1 , PAR 2 -mediated exocytosis required f-actin reorganization, and involves a calcium-dependent rather than a cAMP-dependent second messenger. A similar requirement for f-actin reorganization was observed using ionomycin to mimic the calcium flux initiated by the PAR receptors, indicating that the requirement for f-actin remodeling likely occurred downstream of the PAR-stimulated calcium signal. These observations are in agreement with previous work that inferred activation of the PAR 2 receptor using trypsin to stimulate Weibel-Palade body exocytosis 19 and that detected a calcium flux in endothelial cells after trypsin stimulation. 35 Coupling of PAR 2 to endothelial cytoskeletal-associated proteins has not been examined previously. However, regulated exocytosis by mast cells or pancreatic acinar cells can be facilitated by dissolution of the cortical actin barrier and is thought to be a prerequisite for vesicle fusion to the plasma membrane. 36, 37 The endothelial PAR 2 stimulated calcium signal is required for exocytosis and may regulate disassembly of cortical f-actin, 38 for example by augmenting the activity of actin-severing proteins. 39 The sensitivity of PAR 2 stimulated exocytosis to the actin-stabilizing effect of jasplakinolide is consistent with this model.
Regulation of f-actin reorganization occurs under the influence of the Rho family of monomeric GTP-binding proteins. 40 For example, Rac1 is linked to PAR signaling pathways that regulate stress fiber induction and cortical actin remodeling. 32 In addition, GTP-␥S-induced exocytosis in permeabilized mast cells is inhibited by C3 exotoxin, which specifically ADP-ribosylates and inactivates Rho. 33 Rac and Cdc42 activity are also implicated in regulated exocytosis in basophilic leukemic cells and pancreatic ␤-cells. 34, 41, 42 Our observation that pretreatment of the HUVECs with TcdB, to inactivate Rho, Rac, and Cdc42, markedly inhibits PARstimulated vWF release, clearly implicating Rho-GTPases in both the PAR 2 and PAR 1 signaling pathways that direct Weibel-Palade body exocytosis.
Rho-GTP rapidly increases after stimulation of HUVECs with either the PAR 2 or PAR 1 agonist. To determine the participation of Rho directly in PAR-stimulated WP body exocytosis, we used the C3 exotoxin to selectively modify and abrogate interaction of Rho with downstream effector molecules. We found no consistent inhibitory effect of C3 exotoxin when used at concentrations known to markedly ADP-ribosylate endothelial Rho proteins. 24 Moreover, inhibition of Rho kinase with Y27632 also fails to block PAR-stimulated exocytosis. This result indicates that neither RhoA nor Rho kinase activity is required for WP body exocytosis after stimulation of either PAR, and confirm recent data examining the role of RhoA in thrombinstimulated exocytosis. 43 In contrast, we observed that expression of the Cdc42 17N mutant significantly decreased PARstimulated Weibel-Palade body exocytosis. Because the transfection efficiency in these experiments was approximately 30% to 50%, diminished Cdc42 activity likely accounts for much of the inhibition observed with TcdB treatment. Taken together these experiments implicate an obligatory role for Cdc42 activity in the cascade of events leading to endothelial exocytosis downstream of either proteinase activated receptor. However, we cannot exclude that Rho-GTPase family members function partially redundantly in this system.
Interestingly, despite the ability to mobilize intracellular calcium and elicit f-actin remodeling and myosin light chain phosphorylation, PAR 2 signaling, in contrast with PAR 1 , fails to increase endothelial monolayer permeability. Our observations confirm and extend those of Compton et al 20 who observed no endothelial monolayer permeability change after trypsin stimulation. We observe that PAR 1 -mediated monolayer permeability required Rho-GTP and Rho kinase activity for this event and demonstrate that PAR 2 recruited Rho-GTP, albeit only weakly. These results indicate that unlike PAR 1 , PAR 2 fails to sufficiently activate the RhoA, and possibly other, signal transduction pathways necessary for monolayer pore formation.
In summary, we describe a role for cytoskeleton remodeling and the Rho family of GTP-binding proteins in both PAR 1 and PAR 2 signaling to endothelial Weibel-Palade body exocytosis. The signal involves Cdc42 GTP-binding protein acting independently of Rho kinase or Rac1. Our data are consistent with a model of Cdc42 GTP-binding proteindependent cortical cytoskeletal remodeling. However, in comparison with PAR 1 , PAR 2 elicits less RhoA-GTP and MLC phosphorylation and does not elicit increased monolayer permeability.
